Concerns are growing about the safety of weight-loss medications known as GLP-1 agonists, amid reports of serious side effects including pancreatitis and other health complications. These drugs, which have surged in popularity for their effectiveness in promoting weight loss, carry warnings about gastrointestinal issues such as nausea, vomiting, and constipation, but recent cases suggest potentially more severe risks.
A Norfolk coroner’s court recently examined the death of Caroline Savage, 73, who passed away two years ago from faecal peritonitis, a rare complication arising when fecal matter leaks into the abdominal cavity. Savage had been prescribed Mounjaro (tirzepatide), a GLP-1 agonist, and her pharmacist advised increasing her dose to 10 mg after four months of treatment. While the direct link between the medication and her death remains uncertain, pancreatic inflammation is a recognized potential adverse effect of these drugs.
Data submitted to the UK Medicines and Healthcare products Regulatory Agency (MHRA) indicate that as of January 31, 2025, there were 22 recorded deaths associated with adverse reactions to GLP-1 agonists used for weight loss. Vicky Price, president-elect of the Society for Acute Medicine, expressed concern that some patients may be taking these medications without fully understanding the risks or the importance of medical supervision as part of a comprehensive weight management plan.
Registered dietician Duane Mellor, an honorary associate professor of nutrition at the University of Leicester, emphasizes the necessity of medical oversight when using these drugs. He notes that the relationship between serious side effects and GLP-1 agonists has yet to be definitively established but advises users to ensure close monitoring during treatment. Typically, doses begin at 0.25 mg weekly and gradually increase over several months up to 2.4 mg, or in certain cases, higher doses up to 7.2 mg weekly. This stepwise approach is designed to manage symptoms and tailor treatment to the individual’s response.
Pancreatitis, an acute inflammation of the pancreas, is a rare but documented risk affecting approximately 0.2 to 1 percent of users. Mellor explains that rapid weight loss itself, whether through diet or medication, can elevate the risk for pancreatitis and gallstones. Gallstones can obstruct pancreatic ducts, leading to symptoms such as severe abdominal and back pain that may not subside, as well as vomiting.
Other serious side effects highlighted by the MHRA include hypoglycemia in non-diabetic users, and vomiting or diarrhea which can cause dehydration. Severe dehydration may result in kidney damage requiring hospitalization. A large-scale study presented at a recent medical meeting also linked weight-loss drugs to an increased risk of skeletal disorders, including osteoporosis and tendon ruptures. Additionally, experts have cautioned about the potential for eating disorders developing with long-term use, due to the drugs’ impact on nutrient absorption.
Certain health conditions necessitate caution or avoidance of GLP-1 agonists. Individuals with a history of pancreatitis, cardiovascular disease, gallbladder issues, liver or kidney impairment should undergo thorough evaluation before treatment. Those with personal or family histories of thyroid cancer or tumors, as well as people with diagnosed eating disorders, are advised against use. Potential interactions with medications such as warfarin, thyroid drugs, and insulin also require consultation with a healthcare provider.
The practice of “microdosing”—administering smaller-than-recommended amounts of GLP-1 inhibitors to maintain weight loss—is an off-label trend not supported by regulatory authorities or the NHS. Mellor warns that the lack of guidance on safe dosing and concerns about needle use make this approach potentially hazardous.
As GLP-1 agonist medications continue to gain traction, experts underscore the importance of medical supervision and patient education to mitigate risks and ensure safe use.